AC BioScience SA
AC BioScience Ltd., a clinical-stage biotech company and a developer of immune modulating and angiogenic cancer therapies. AC BioScience LTD. is a Swiss biotech company, pioneering the development of novel therapies in immuno-oncology and tumor vascular normalization. AC BioScience is a start-up biotech company with an innovative vision and business model. We are dedicated to developing groundbreaking new therapies to fight a range of cancers. Two of our three lead molecules in oncology will enter clinical stage in 2022.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Nationally (across the country)
Improving patient lives and increasing survival rates
Our vision is to achieve a significant increase in the survival rate of patients with specific cancers through ground-breaking scientific discovery and personalized medicine using our proprietary molecules.
One of AC BioScience’s innovative approaches is characterized by the way we develop and apply new vascular normalizers that help drugs to better access solid tumors and oxygenation, thereby increasing the efficacy of all types of chemo- and radiotherapy.
Reverting the tumor phenotype
With a Beta-carboline derivative showing outstanding pre-clinical results, our aim is to revert the tumor phenotype in order to improve MHC-1 mediated antigens presentation, and thereby potentiate the efficacy of anti PD-1 therapy.
We are also currently validating a patented cationic amphipathic peptide (CAP6). This molecule is at the forefront of a shift towards cancer “biotherapy”, and has shown exceptional promise in in vivo tests for the treatment of lung cancer (NSCLC).
These products are potential blockbusters, with the promise of significantly improving the quality of life and clinical outcomes of millions of patients around the world.
Our profound knowledge of specific therapeutic areas sets AC BioScience apart in its quest to create new possibilities and give hope to cancer patients.
Founded by Andreas Schläpfer and Professor Christian Auclair, the company is leading a paradigm shift in cancer therapeutics. AC BioScience is headquartered at the life sciences campus Biopôle near Lausanne, and celebrated its fifth year of existence in March 2022.
Our primary focus is on developing personalized therapies for tumoral pathologies. We have obtained patent protection for one ground-breaking cancer therapy and have filed patents for two others.
The company has a subsidiary company – AC BioTech SAS – whose offices are located in the Villejuif Bio Park near Paris, in proximity to the main French cancer research institutions. AC BioTech will serve as a liaison point and vehicle for clinical validation activities in France.
AC BioScience is focused on personalized molecular therapies; that is, medical care designed to optimize efficiency or therapeutic benefit for particular groups of patients by using molecular profiling.
We bring to clinical validation unique scientific discoveries identified by our co-founder to dramatically impact the efficacy of cancer treatment therapies. Clinical trials are scheduled to start for two of its proprietary molecules in 2022.
The company develops novel uses for existing molecules with well-established safety and tolerance profiles. Our compound for tumor vascular normalization has a history of FDA-approved Phase 1 data in a different application
To maximize resources and ensure sustainability, the company operates with a lean organization. This is possible through the deep involvement of the two co-founders in strategic and scientific development and operations, and the obtainment of research grants. Drug development and clinical validation are outsourced to specialist companies or academic institutions.
For one of its molecules, the company is challenging the traditional antiangiogenic approach to cancer therapy. Our neo-adjuvant therapy is designed to improve the efficacy of all types of chemo- and radiotherapy for solid tumors.
One of our new molecules (ACB1801) also holds promise, within immune-oncology, to induce F-actin network remodeling and thereby potentiate the therapeutic benefit of anti-PD-1.